Background Lanthanum carbonate is a highly effective phosphate binder with significant
potential as a treatment for hyperphosphatemia in patients with end-stage renal disease …

Hyperphosphataemia is a usual accompaniment of end stage renal disease and dialysis, in
the absence of dietary phosphate restriction or supplemental phosphate binders. It is …

Background Hyperphosphatemia and poor nutritional status are associated with increased
mortality. Lanthanum carbonate is an effective, calcium-free phosphate binder, but little is …

Abstract Background/Aims: Hyperphosphatemia is an important clinical consequence of
renal failure, and its multiple adverse systemic effects are associated with significantly …

Hyperphosphatemia has been shown to be involved not only in the onset and progression of
secondary hyperparathyroidism but also in vascular calcification. In addition, it influences …

Background: Vascular calcification (VC) contributes to cardiovascular disease in
haemodialysis (HD) patients. Few controlled studies have addressed interventions to reduce …

Aims: No conventional phosphate binder is entirely satisfactory for the treatment of
hyperphosphatemia in patients with end-stage renal disease (ESRD). Consequently, there …

Abstract Background Lanthanum carbonate (FOSRENOL®) is an effective, well-tolerated
phosphate binder. The ability of lanthanum to reduce serum phosphorus levels to≤ 5.5 …

Abstract▴ Lanthanum carbonate is a novel, non-aluminium, non-calcium phosphate binding
agent that forms a water-insoluble compound, lanthanum phosphate, in the gut.▴ …

Background. The effects of calcium compared with non-calcium-based phosphate binders
on mortality, cardiovascular events and vascular calcification in patients with chronic kidney …